Executive Function Play for Down Syndrome

(EXPO Trial)

This trial tests a program called EXPO, designed to improve executive function—skills like memory and problem-solving—in children with Down syndrome. Participants will be divided into groups: some will start the program immediately, while others will join later. Researchers will assess the program's effectiveness by comparing these groups and adapting the program based on each child's progress. The trial suits children with Down syndrome who do not have complete hearing or vision loss and primarily speak English or Italian. As an unphased trial, it offers a unique opportunity for children to potentially enhance their cognitive skills through a tailored program.

Research has shown that the EXPO treatment, which uses play-based activities to enhance memory, planning, and self-control, is generally safe for children with Down syndrome. Studies have found that these activities, lasting only 5 to 15 minutes, require no special toys or materials and easily integrate into daily routines, resulting in a low risk of negative effects.

For the EXPO Extended pathway, which involves a longer duration of activities, similar studies have observed slight improvements in these skills without major safety concerns, indicating that the extended activities are also safe.

Regarding the EXPO Foundations pathway, which emphasizes early communication, specific safety data is limited. However, given the nature of the activities in the overall EXPO treatment, a similar level of safety is expected.

Researchers are excited about the EXPO treatments for Down syndrome because they focus on enhancing executive function through structured play, which is a novel approach compared to traditional therapies that often focus on improving physical or speech abilities. The EXPO Standard Pathway offers a targeted 12-week intervention refined from previous versions, aiming for early and notable improvements. Meanwhile, the Adaptive Pathways cater to slower responders by extending the intervention to 18 weeks or by simplifying activities to emphasize early communication and regulation. This adaptability and focus on cognitive skills mark a promising shift from conventional treatments.